Review Article   **Open Access**

Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma

Roberto Ria* and Angelo Vacca

Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy

Abstract

Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed symptomatic multiple myeloma (MM). The introduction into clinical practice of novel agents (i.e.: proteasome inhibitors and immunomodulatory derivatives [IMiDs]) has significantly contributed to major advances in MM therapy and prognosis. These novel agents are incorporated into induction regimens to enhance the depth of response before ASCT and further improve post-ASCT outcomes. Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful autologous transplantation. The mobilizing regimen usually consists of cyclophosphamide or disease-specific agents, in combination with a hematopoietic cytokine, usually G-CSF, which mobilizes HPSCs into the bloodstream, in particular when administered after myelosuppressive chemotherapy. In some patients, the number of mobilized CD34+ cells is not sufficient to perform successful stem cell transplantation due to bone marrow damage by neoplastic proliferation and/or chemoradiotherapy. To improve the collection of CD34+ cells, the mobilization procedure can be repeated or an alternative chemotherapy regimen can be chosen. Recently, the new drug plerixafor (Mozobil®) has been introduced to increase the number of circulating CD34+ cells. Its use increases the level of functional HPCs in the peripheral blood, with long-term resettlement

Keywords: Stem cell transplantation; Chemotherapy; Granulocyte-colony stimulating factor; Multiple myeloma; Stem cell mobilization

Introduction

High-dose chemotherapy, supported by autologous hematopoietic stem cell transplantation (ASCT), is an effective treatment strategy for a variety of hematologic malignancies [1-4]. The collection of adequate numbers of HSCs is a prerequisite for proceeding to autologous transplantation; however, approximately 5% to 40% of patients do not meet the minimum threshold of 2×106 CD34+ cells/kg that is associated with timely engraftment [5-9].

The goal of CD34+ cell mobilization is to collect enough cells to achieve a rapid and sustained hematopoietic recovery after high-dose therapy, since delayed hematopoietic recovery correlates with increased toxicity and transplant-related mortality. It has been demonstrated that high CD34+ cell doses ($>3/5\times10^6$/kg) are associated with faster hematological recovery and lower incidence of infectious and bleeding complications [10]. Doses $<2\times10^6$/kg are associated with slower recovery and worse outcomes. CD34+ cell doses over 15×10^6/kg after high-dose melphalan administration can eliminate severe thrombocytopenia. The International Myeloma Working Group (IMWG) has suggested a minimum target of 4×10^6 and, if feasible, an average of $8-10\times10^6$/kg that should be collected, allowing most myeloma patients to undergo two autografts during the course of their disease, also considering that in some patients, the first ASCT can be unsuccessful [11].

A variety of mobilization strategies are currently used, including growth factors alone or in combination with chemotherapy and, more recently, the partial CXC chemokine receptor-4 (CXCR-4) agonist, plerixafor. Of the available growth factors, the most commonly used is the recombinant granulocyte-colony stimulating factor (G-CSF) analog, filgrastim [12]. Other growth factors include pegfilgrastim, a polyethylene glycol conjugate of G-CSF; lenograstim, glycosylated recombinant G-CSF; molgramostim, recombinant granulocyte macrophage colony-stimulating factor; sargramostim, glycosylated granulocyte macrophage colony-stimulating factor; and ancestim, recombinant human stem cell factor. Lenograstim is widely used for HSC mobilization in Europe; sargramostim, molgramostim, and ancestim are rarely used for mobilization today.

A combination of chemotherapy along with growth factor is a commonly used strategy for mobilization. Chemotherapy is added to improve CD34+ cell yield [13,14], for in vivo purging of mobilized tumor cells to reduce tumor burden (although there are limited supportive data), and to show chemosensitivity before transplantation. However, approximately 30% of patients undergoing a mobilization strategy that includes chemotherapy will develop neutropenic fever [15], and many of those will require hospitalization. The most commonly used chemotherapy regimens include cyclophosphamide at a variety of doses, particularly in patients with multiple myeloma (MM) [16,17]. Mobilization regimens for patients with lymphoma are varied and include ifosfamide, carboplatin, and etoposide, dexamethasone, doxorubicin, cytarabine, and cisplatin (DHAP), etoposide, methyl prednisolone, cytarabine, and cisplatin and others [18,19].

In some patients, the number of mobilized CD34+ cells is not sufficient to perform successful stem cell transplantation due to bone marrow damage by neoplastic proliferation and/or chemoradiotherapy. To improve the collection of CD34+ cells, the mobilization procedure can be repeated or an alternative chemotherapy regimen can be chosen. Recently, in patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) with a poor yield of CD34+ cells, the new drug plerixafor (Mozobil®) can be administered before apheresis to increase

the number of circulating CD34+ cells. Plerixafor is a derivative of bicyclam, reversible and selective antagonist of the CXCR4 chemokine receptor that acts by blocking the binding between this receptor expressed on hematopoietic stem cells and its ligand, namely the stromal cell-derived factor-1α (SDF-1α), also called CXCL12, expressed on stromal cells. Its use increases the level of functional HPCs in the peripheral blood, with long-term resettlement [20-24].

Therapeutic Strategies in MM Untreated Younger Patients

Induction therapy followed by ASCT has been regarded as standard therapy for younger patients with good health condition [25]. Patients who are considered potential candidates for ASCT receive 2-4 cycles of a non-melphalan-containing regimen and then proceed to stem cell harvest [26]. Subsequently many patients undergo ASCT. However, depending on the response to initial therapy and the patient's choice, initial therapy can be resumed after stem cell harvest, delaying ASCT until first relapse. The role of early versus delayed ASCT is an argument of debate [27]. In the novel agent era, the issue of early versus late ASCT needs to be reevaluated in the context of large randomized clinical trials [28].

On the contrary, the second ASCT in patients who do not achieve almost a Very Good Partial Response (VGPR) after the first transplant seems to be the best option [29].

The introduction of novel agents into the induction regimens significantly improves the outcome of patients with newly diagnosed MM [30], probably because of increased rates of immunophenotypic and/or molecular remissions compared with that reported in the recent past.

The role of Bortezomib, the first proteasome inhibitor used in clinical practice in MM, alone and in combination with dexamethasone (VD), was initially explored in patients who were either eligible or ineligible for ASCT [31]. VD shows superior response rates when compared with vincristine/doxorubicin/prednisone (VAD) with a VGPR rate of 38% vs. 15% after induction therapy in young patients. The higher VGPR rate was confirmed after transplantation (54% vs. 37%), with a PFS improvement (36 vs. 30 months) [32], but the improvement of OS has not been revealed. Sensory neuropathy is the most frequent bortezomib-related toxicity [33]. Studies that compared the 3 drug combination bortezomib/thalidomide/dexamethasone (VTD) with thalidomide/dexamethasone (TD) or VD [34,35] have shown the ability of VTD plus double ASCT followed by bortezomib-based consolidation to overcome the poor prognostic effects of t(4;14) translocation [35]. After three cycles of induction therapy, VTD was superior to TD with respect to all categories of response, including CR, CR-nCR (31% vs. 11%), and at least VGPR (62% vs. 28%).

Beyond the best response rates in terms of PFS, it was demonstrated that the use of VTD is particularly useful in patients with acute renal failure as it acts quickly without dose reduction [35]. The addition of thalidomide, lenalidomide, or cyclophosphamide to bortezomib and dexamethasone has been associated with high response rates and longer progression-free survival (PFS). The three drug-combination bortezomib/cyclophosphamide/dexamethasone (CyBorD or VCD) and the four-drug combination bortezomib/cyclophosphamide/lenalidomide/dexamethasone (VCRD) [36] have been studied in the randomized phase 2 trial EVOLUTION [37] in newly diagnosed myeloma patients. VCD was well tolerated with similar activity compared with the combination bortezomib/lenalidomide/dexamethasone (VRD), a combination which produces remarkably

high overall and complete response rates [38]. The CR was achieved in 22% and 47% of patients treated with two different schedules of VCD versus 24% of patients treated with VRD. Although highly active, CR rates with VCRD were similar compared with either VCD or VRD. In newly diagnosed MM, TD produces response rates of 65%-75% [39]. Two randomized trials found TD to be superior to dexamethasone alone [40]. In the transplant setting, there are some trials which aim to clarify the role of lenalidomide as induction therapy [41]. Although its use during induction determines good response rates, it seems to impact on the mobilization of stem cells [42-44].

Allogeneic transplantation (allo-SCT) is an alternative therapy that may improve survival for very high risk and selected patients. The role of allo-SCT remains controversial due to the Treatment-Related Mortality (TRM) (10–20%) and Graft-Versus-Host Disease (GvHD) rates. Young patients with High-Risk disease, ISS II and III associated with del 1p/1q gain, t(4;14), del(17p) or t(14;16), in whom projected 4-year PFS and OS do not exceed 11% and 33%, respectively may potentially benefit from allo-SCT. Clinical trials with long-term follow up are important to prove that allo-SCT should not be abandoned in MM [45].

Mobilization Strategies

Growth factors alone

Since only one trial [46] has been conducted in patients with MM, there are much data available on the mobilization with G-CSF alone on patients with lymphomas and solid tumors. The first randomized study Spitzer et al. [47] compared either G-CSF 10 microg/kg/day alone, or G-CSF at the same dose with GM-CSF 5 microg/kg/day in fifty patients with lymphoid or selected solid tumor malignancies. The bone marrow buffy coat and PBSC product mononuclear cell count ($\times 10^8$/kg) and CD34+ cell count ($\times 10^6$/kg) collected by each method of stem cell mobilization was not significantly different indicating that there is no clinical benefit with PBSC products mobilized with the combination of G-CSF and GM-CSF vs. G-CSF alone.

Filgrastim has been compared to molgramostim in non-Hodgkins lymphoma and Hodgkin's disease patients both at a dose of 250 mcg/m²/day [48]. Sixty-two patients receiving PBSC or BMSC were enrolled in this study. Results indicated that G-CSF and GM-CSF are both effective in priming autologous PBSC or BMSC for collection.

In a randomized study Ataergin et al. [49] compared filgrastim 10 mcg/kg/day to a 25% reduced dose of lenograstim (7.5 mcg/kg/day) in 40 consecutive patients with hematologic malignancies and solid tumors. Successful mobilization with the first apheresis was achieved in 50% patients in the filgrastim group versus 46% patients in the lenograstim group. No significant difference was seen in the median number of CD34+cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the post-transplant period. Authors concluded that filgrastim 10 mcg/kg/day and lenograstim 7.5 mcg/kg/day resulted in successful mobilization of CD341 cells in patients undergoing ASCT. In particular, priming with lenograstim at 25% lower dose does not negatively affect the number of CD34 stem cells harvested, or engraftment results and may achieve an economic benefit in regard to G-CSF requirement or number of vials needed for a successful mobilization and ASCT.

One study investigated the addition of stem cell factor (ancestim

20 mcg/kg/day) to filgrastim in 102 patients diagnosed with heavily pretreated lymphoma patients [50]. Authors concluded that based on the increased proportion of patients reaching target yields of PBPC and reduction in the number of leukaphereses required, stem cell factor plus filgrastim can be considered an important mobilization option for heavily pretreated lymphoma patients receiving ablative therapy with PBPC support.

Of the studies that used a non-chemotherapy mobilization strategy, significant improvement in CD34+ cell yield was achieved with plerixafor in combination with G-CSF in patients with MM (11.0 vs. 6.2×10^6/kg; P<.001) [46] or NHL (5.69 vs. 1.98×10^6/kg; P<.01) [51].

Growth factors in combination with chemotherapy

The efficacy of the addition of cyclophosphamide to G-CSF in the mobilization procedures have been extensively demonstrated in hematologic diseases and solid tumors [19,52-60]. Of these studies some resulted in a statistically significant improvement in CD34+ cell yield [52,57,58]. In the study by Facon et al. [57], the addition of ancestim resulted in a median CD34+ cell yield of 12.4×10^6/kg compared with 8.2×10^6/kg for cyclophosphamide plus filgrastim without ancestim (P=.007). In the Martinez et al. [58] study, the addition of growth factor (molgramostim) to cyclophosphamide resulted in a significant improvement in median CD34+ cell yield (1.4 vs. 0.5×10^6/kg; P=.0165). Narayanasami et al. [52] reported CD34+ cell yield was improved with cyclophosphamide combined with filgrastim over filgrastim alone (7.2 vs. 2.5×10^6/kg; P=.004).

Moreover, various studies compared combination of non–cyclophosphamide-based chemotherapy plus one or more growth factors [61-70]. In the category of non–cyclophosphamide-based chemotherapy with growth factor, 2 studies found significantly improved CD34+ cell yield with their interventions. In the Copelan et al. [67] study including exclusively patients with NHL, rituximab improved the yield (9.9 vs. 5.6×10^6/kg; P=.021). Doubling the dose of filgrastim improved the CD34+ cell yield in the Demirer et al. [62] study in a heterogeneous group of patients (8.2 vs. 4.7×10^6/kg; P<.0001).

Various studies have been conducted in order to identify the ideal partner for chemotherapy in the mobilization procedures. Kopf B et al have shown that a lower dose of glycosylated G-CSF is as effective as the standard dose of non-glycosylated G-CSF for PBPC mobilization in patients undergoing ASCT [65].

A randomized trial conducted by the Italian group has shown a lower incidence of febrile episodes during the period of neutropenia in MM patients receiving lenograstim versus those administered filgrastim after high-dose cyclophosphamide for stem cell mobilization [71]. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. The lenograstim group presented not just a significantly higher absolute CD34+ cell number compared with the filgrastim group but also a less number of days (8 days against 9 of the arm B) needed to reach the target threshold of CD34+ cells, while no differences were detected in terms of collection efficacy.

Our group has investigated the role of G-CSF glycosylation [72] that modifies the chemical and biological properties of G-CSF [73]. Our results show that cyclophosphamide in association with lenograstim results in more adequate mobilization, and the HSC collection target is reached more quickly and requires fewer leukaphereses in patients with MM, NHL or HL that are typical candidates for ASCT and for combined mobilization with chemotherapy and G-CSF. The higher efficacy of glycosylated Hu G-CSF was not influenced by the disease nor by dose of cyclophosphamide administered, bone marrow involvement at diagnosis, and radiotherapy.

Although pegfilgrastim is licensed for the prophylaxis of febrile neutropenia after cytotoxic chemotherapy, it is also an effective mobilizer of CD34+ cells. In fact, pegfilgrastim compared favorably with the other G-CSFs after mobilizing chemotherapy for autologous HSC collection. The administration of pegfilgrastim following high-dose therapy and ASCT shortened the time to myeloid recovery when compared with conventional G-CSF. Plasma G-CSF levels were about 1 log higher with pegfilgrastim, but in the setting of autologous ASCT, this did not result into a faster hematopoietic recovery. Only few data are available on the biological effects of pegfilgrastim, which suggest that pegfilgrastim stimulation results in different functional properties of hematopoietic stem and progenitor cells compared with conventional G-CSF [74,75].

Bassi et al. [76] compared the use of this type of growth factor with standard G-CSF in 64 patients with NHL using high-dose chemotherapy. At mobilization chemotherapy, the first 26 patients used unconjugated G-CSF, while the remaining 38 patients received pegfilgrastim. At the time of harvest, 25 patients collected stem cells after the use of G-CSF and 36 in the peg group. No statistically significant differences were observed in median peripheral CD34+ cells mobilized (77 vs. 71 μL) and in collected CD34+ cells (12.3×10^6/kg vs. 9.4×10^6/kg; p=0.76). In the peg group, all patients collected the target CD34+ cells with a single apheresis with a greater proportion of "optimal" mobilizers (83 vs. 64%; p=0.05) showing that a single dose of pegfilgrastim could be a valid alternative to unconjugated G-CSF to mobilize CD34+ cells in lymphoma patients.

Differences in HPSCs mobilization in response to pegfilgrastim compared to lenograstim and filgrastim in patients with MM and lymphomas have been recently evaluated [77]. The results shows that the glycosylated form of G-CSF provides the best results in the mobilization compared to pegylated form and to non-glycosylated form in terms of collection of target HPSCs and the number of leukaphereses required to achieve it. No significant differences among the different diseases in terms of minimum number of CD34+ cells collected and the number of apheresis necessary to achieve the target, (4–6×10^6 CD34+/Kg b.w.) and even among patients treated with 3, 4 or 7 g/m^2 of cyclophosphamide have been shown. An average of two aphereses was sufficient both in patients with and without bone marrow involvement.

All these findings indicate that, despite all the G-CSF are safe in the mobilization procedure, lenograstim may represent the ideal partner of cyclophosphamide for mobilization of PBSCs in patients with MM candidate to autologous transplantation.

CXC chemokine receptor-4 (CXCR-4) agonist, plerixafor

Data from several clinical trials have demonstrated the superiority of new agents either in combination or not with conventional chemotherapy as up-front therapy for newly diagnosed MM young patients [29,32,35,38,42,78-82].

Lenalidomide is a more active analogue of thalidomide. This provides the basis for its role in newly diagnosed MM patients [42,83]. On the other hand, myelosuppression induced by lenalidomide represents the dose-limiting toxicity and requires monitoring during therapy [84].

Prolonged lenalidomide induction therapy has been reported to affect stem cell mobilization. Patients undergoing peripheral blood stem cell mobilization with G-CSF following lenalidomide

induction had significant decrease in total CD34(+) cells collected, average daily collection, and increased number of aphereses [85]. The exact mechanisms by which lenalidomide interferes with stem cell mobilization are not clear. However, it seems that there are no harmful effects on the quality of PBSC collected as denoted by similar engraftment rate across all treatment groups. Sekeres et al. [84] estimated that more than half of patients treated with lenalidomide-based protocols developed grades 3 and 4 cytopenia, mostly neutropenia and thrombocytopenia. Interestingly, it has been shown that patients who develop severe hematologic toxicity are more likely to better mobilize after cyclophosphamide therapy, but mechanisms beyond this clinical evidence remain still obscure. Based on these reports, no more than six months of Lenalidomide including regimen prior to Cyclophosphamide mobilization should be recommended to avoid poor PBSC collection [86].

The recent introduction of plerixafor which increases the number of mobilized circulating hematopoietic stem and progenitor cells when administered with G-CSF may improve PBSC collection and change this scenario.

In December 2008, the FDA approved the use of plerixafor, in combination with G-CSF, to mobilize HSCs from peripheral blood of patients with NHL and MM, who will subsequently undergo an autologous stem cell transplant. This decision was based on evidence from phase I, II and III clinical trials. Clinical data suggest that plerixafor has similar activity in Hodgkin's lymphoma and solid tumors.

Two phase III, multicenter, randomized, double-blind, placebo-controlled studies were performed to compare the safety and efficacy of plerixafor and G-CSF with placebo and G-CSF in the mobilization of CD34+ cells [46,51]. The studies were very similar in design and the results shown that the proportion of patients receiving plerixafor + G-CSF achieving collection target was higher than those receiving placebo + G-CSF. Moreover, the median number of cells mobilized and the increase in collection on days 4 and 5 (pre and post intervention) were significantly higher in the plerixafor arm compared to the placebo arm.

In current clinical practice, the use of plerixafor is limited to difficult to mobilize patients. Data on the success of mobilization in these patient groups can be obtained from the compassionate use program (CUP) trials. In a paper by Duarte et al. [87], 56 patients from Spain and the UK, who were previous mobilization failures i.e. who mobilized less than 2×10^6 CD34+ cells/kg, were enrolled in a CUP. 75% of previous failures were successfully rescued using G-CSF plus plerixafor, and ultimately 35 patients (63%) underwent transplant with an average of $3.1 \pm 1.2(1.9-7.7) \times 10^6$ CD34+ cells/kg. Remarkably, 71% of patients met the secondary end point of collecting $\geq 10 \times 10^6$ CD34+ cells/kg.

In Germany, Hübel et al. [88] reported on 60 patients (a mix of previously failed mobilizations and predicted poor mobilizers) from 23 centers. In patients receiving 4 days of G-CSF prior to initiating plerixafor, NHL patients mobilized a median of 2.79×10^6 CD34+ cells/kg, MM patients a median of 4.47×10^6 CD34+ cells/kg, and Hodgkin's disease patients a median of 2.41×10^6 CD34+ cells/kg. All patients, irrespective of the underlying disease, needed a median of two apheresis treatments. Other compassionate reports have been similar: Calandra et al. [89] for example, reported that 66% of patients with NHL, MM, and Hodgkin's disease, who had previously failed to mobilize sufficient numbers of CD34+ cells with chemotherapy or cytokine therapy for transplant, could be successfully remobilized with plerixafor and G-CSF.

Additional to failed mobilizers and predicted poor mobilizers, the pre-emptive use of plerixafor may include slow mobilizers of difficult to mobilize patient groups such as myeloma patients pretreated the lenalidomide [90]. Current developments include intravenous mobilization with plerixafor combined with G-CSF in lymphoma patients [91] or combination of plerixafor, G-CSF, and rituximab for B-cell-reductive, chemotherapy-free mobilization in lymphoma [92].

Even though the majority of the clinical trials of plerixafor mobilization focused on patients receiving G-CSF alone, it is clinically well recognized that the administration of chemotherapy, most often high-dose cyclophosphamide with or without other agents prior to growth factor, enhances CD34+ mobilization. The particular type of regimen used varies according to the primary diagnosis, but this strategy has often been utilized for patients who have already failed mobilization with G-CSF alone or who, due to a large tumor burden, may benefit from additional cytoreduction before transplant. The drawbacks of chemotherapy utilization are mainly related to the toxicities and complications derived from the use of chemotherapy itself as well as the increase in the duration and cost of the mobilization regimen. However, chemotherapy-based mobilization is widely used and for some transplant programs represents the standard of care. An important question is whether the addition of plerixafor to a chemotherapy +G-CSF regimen will further improve efficacy.

One feasibility study combining plerixafor and chemomobilization has been published [93]. In this study, 26 MM patients and 14 NHL patients received plerixafor, which resulted in an about 2-fold increase in collection yield after plerixafor injection when compared to the collection on the previous day. However, based on blood CD34+ counts and yields, most of the patients in that trial were standard mobilizers or even good mobilizers. Recently, a small series of patients who mobilized poorly with chemomobilization and received plerixafor [94] suggested efficacy of this strategy. Also, a study including chemomobilized patients receiving plerixafor and with a previous mobilization failure [88] suggest that this combination is effective. An increasing number of studies are evaluating plerixafor administration in conjunction with chemomobilization, showing the acceptance of this approach [95,96].

Due to lower numbers of CD34+ cells mobilized by plerixafor alone than G-CSF alone, the use of plerixafor alone for mobilization would appear limited to patients who are intolerant of G-CSF [97]. Moreover, *up-front* use of plerixafor is currently recommended in only in adult patients with dialysis-dependent renal failure [98].

Finally, the effect of plerixafor plus G-CSF on tumor cell contamination has been investigated in NHL [46,51] and MM patients [99]. Although the total number of patients examined overall was limited, there did not appear to be an increase in tumor cells in the apheresis product following plerixafor above that observed or expected with G-CSF. Thus, contamination of an apheresis product would be expected to be similar to that obtained by standard G-CSF mobilization.

Conclusion

Initial therapy for MM depends on the eligibility for ASCT. Patients who are considered potential candidates for ASCT receive 2-4 cycles of a non-melphalan-containing regimen and then proceed to stem cell harvest. Several factors may influence mobilization outcome, including age, stage disease, prior chemotherapy (e.g., fludarabine or melphalan), irradiation or a higher number of prior treatment lines. In MM G-CSF cytokines alone (filgrastim, lenograstim) or in combination with chemotherapy (cyclophosphamide or etoposide) are indicated for PBSC mobilization. The use of new drugs for the

induction therapy leads good response rates, although affecting the mobilization of stem cells. PBSC mobilization can be optimized with an appropriate individualized strategy. Eg, in patients older than 65 years and those who have previously received more than 4 cycles of lenalidomide-containing regimens, stem cells must be mobilized with either cyclophosphamide + G-CSF or with plerixafor. The choice of the appropriate mobilization regimen, based on disease stage, and the apheresis protocol optimization can improve the mobilization outcome.

Acknowledgement

References

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335: 91-97. [PubMed]

2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883. [PubMed]

3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-1545. [PubMed]

4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359: 2065-2071. [PubMed]

5. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, et al. (1996) Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 17: 937-941. [PubMed]

6. Perea G, Sureda A, Martino R, Altés A, Martínez C, et al. (2001) Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 80: 592-597. [PubMed]

7. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E (2004) Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 33: 907-912. [PubMed]

8. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, et al. (2008) Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 49: 769-778. [PubMed]

9. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, et al. (2006) Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 37: 719-724. [PubMed]

10. Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, et al. (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25: 1-6. [PubMed]

11. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, et al. (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98: 1614-1615. [PubMed]

12. Gertz MA (2010) Current status of stem cell mobilization. Br J Haematol 150: 647-662. [PubMed]

13. Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, et al. (2006) Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant 37: 661-668. [PubMed]

14. Meldgaard Knudsen L, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE (2000) A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 26: 717-722. [PubMed]

15. Toor AA, van Burik JA, Weisdorf DJ (2001) Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 28: 1129-1134. [PubMed]

16. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, et al. (2001) A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 27: 837-842. [PubMed]

17. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP (2007) Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 9: 539-547. [PubMed]

18. Deliliers GL, Annaloro C, Marconi M, Soligo D, Morandi P, et al. (2002) Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 43: 1957-1960. [PubMed]

19. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, et al. (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 29: 285-290. [PubMed]

20. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, et al. (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 61-65. [PubMed]

21. Martin C, Bridger GJ, Rankin SM (2006) Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 134: 326-329. [PubMed]

22. Lemoli RM (2012) New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis 4: e2012066. [PubMed]

23. Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, et al. (2013) Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant 48: 777-781. [PubMed]

24. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hübel K, et al. (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102: 2728-2730. [PubMed]

25. Shuji O, Kazuyuki S (2014) Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future. Biomed Res Int 2014: 394792. [PubMed]

26. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, et al. (2008) Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 83: 1131-1138. [PubMed]

27. Moreau P, Rajkumar SV (2012) Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment? Leuk Res 36: 677-681. [PubMed]

28. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, et al. (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28: 2077-2084. [PubMed]

29. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, et al. (2007). Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25: 2434-2441. [PubMed]

30. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520. [PubMed]

31. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, et al. (2010) Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 24: 1406-1411. [PubMed]

32. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, et al. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621-4629. [PubMed]

33. Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112: 1593-1599. [PubMed]

34. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, et al. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118: 5752-5758. [PubMed]

35. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, et al. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075-2085. [PubMed]

36. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, et al. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23: 1337-1341. [PubMed]

37. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, et al. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119: 4375-4382. [PubMed]

38. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, et al. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-686. [PubMed]

39. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21: 16-19. [PubMed]

40. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24: 431-436.

41. Zou Y, Sheng Z, Niu S, Wang H, Yu J, et al. (2013) Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma. Leuk Lymphoma 54: 2219-2225. [PubMed]

42. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21: 2035-2042. [PubMed]

43. Ria R, Reale A, Solimando AG, Mangialardi G, Moschetta M, et al. (2012) Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma. Stem Cells Int 2012: 607260. [PubMed]

44. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23: 1904-1912. [PubMed]

45. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, et al. (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 99: 232-242. [PubMed]

46. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, et al. (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113: 5720-5726. [PubMed]

47. Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, et al. (1997) Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 20: 921-930. [PubMed]

48. Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, et al. (1997) Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Biol Blood Marrow Transplant 3: 217-223. [PubMed]

49. Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, et al. (2008) Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 83: 644-648. [PubMed]

50. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, et al. (2000) A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 26: 471-481. [PubMed]

51. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, et al. (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 27: 4767-4773. [PubMed]

52. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, et al. (2001) Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98: 2059-2064. [PubMed]

53. Ahn JS, Park S, Im SA, Yoon SS, Lee JS, et al. (2005) High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization. Korean J Intern Med 20: 224-231. [PubMed]

54. Demuynck H, Delforge M, Verhoef G, Zachée P, Vandenberghe P, et al. (1995) Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 90: 384-392. [PubMed]

55. Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Liu Q, et al. (2000) Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 9: 737-748. [PubMed]

56. Quittet P, Ceballos P, Lopez E, Lu ZY, Latry P, et al. (2006) Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. Bone Marrow Transplant 38: 275-284. [PubMed]

57. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, et al. (1999) Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94: 1218-1225. [PubMed]

58. Martínez E, Sureda A, Dalmases CD, Sánchez JA, Amill B, et al. (1996) Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma. Bone Marrow Transplant 18: 1-7. [PubMed]

59. Min YJ, Kim SW, Suh C, Park J, Kim HJ, et al. (2000) The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci 15: 49-52. [PubMed]

60. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sánchez-Cortés E, Ayala-Sánchez M, et al. (2000) Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs. high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 25: 1141-1146. [PubMed]

61. André M, Baudoux E, Bron D, Canon JL, D'Hondt V, et al. (2003) Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 43: 50-57. [PubMed]

62. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, et al. (2002) Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 116: 468-474. [PubMed]

63. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, et al. (2004) Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 10: 395-404. [PubMed]

64. Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, et al. (1998) Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 22: 625-630. [PubMed]

65. Kopf B, De Giorgi U, Vertogen B, Monti G, Molinari A, et al. (2006) A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant 38: 407-412. [PubMed]

66. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, et al. (2000) Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18: 43-53. [PubMed]

67. Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, et al. (2009) A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 43: 101-105. [PubMed]

68. Hart C, Grassinger J, Andreesen R, Hennemann B (2009) EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Bone Marrow Transplant 43: 197-206. [PubMed]

69. Kim S, Kim HJ, Park JS, Lee J, Chi HS, et al. (2005) Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 84: 742-747. [PubMed]

70. Ozcelik T, Topcuoglu P, Beksac M, Ozcan M, Arat M, et al. (2009) Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant 44: 779-783. [PubMed]

71. Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, et al. (2011) Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res 35: 899-903. [PubMed]

72. Ria R, Gasparre T, Mangialardi G, Bruno A, Iodice G, et al. (2010) Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 45: 277-281. [PubMed]

73. Chamorey AL, Magné N, Pivot X, Milano G (2012) Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw 13: 154-160. [PubMed]

74. Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, et al. (2012) Peg-Filgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 52: 2375-2381. [PubMed]

75. Kobbe G, Bruns I, Fenk R, Czibere A, Haas R (2009) Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 43: 669-677. [PubMed]

76. Simona B, Cristina R, Luca N, Sara S, Aleksandra B, et al. (2010) A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apheres Sci 43: 321-326.

77. Ria R, Reale A, Melaccio A, Racanelli V, Dammacco F, et al. (2014) Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. Clin Exp Med. [PubMed]

78. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, et al. (2011) International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117: 6063-6073. [PubMed]

79. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. (2005) Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 352: 2487-2498. [PubMed]

80. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, et al. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129: 776-783. [PubMed]

81. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New Engl J Med 354: 1021-1030. [PubMed]

82. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, et al. (2008). International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414-423. [PubMed]

83. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, et al. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11: 29-37. [PubMed]

84. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, et al. (2008) Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 26: 5943-5949. [PubMed]

85. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, et al. (2009) Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114: 1729-1735. [PubMed]

86. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, et al. (2008) Stem cell mobilization with Cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14: 795-798. [PubMed]

87. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, et al. (2011) Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 46: 52-58. [PubMed]

88. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, et al. (2011) Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 46: 1045-1052. [PubMed]

89. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, et al. (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41: 331-338. [PubMed]

90. Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, et al. (2011) Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 46: 350-355. [PubMed]

91. Cashen A, Rettig M, Gao F, Reineck T, Abboud C, et al. (2013) IV plerixafor combined with G-CSF is highly effective for stem cell mobilization in lymphoma patients undergoing autologous stem cell collection. EBMT Meeting London.

92. Kaufman JL, Flowers CR, Rados KD, Calandra GB, Vose JM, et al. (2013) A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion 53: 76-84. [PubMed]

93. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, et al. (2010) Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 45: 39-47. [PubMed]

94. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, et al. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 46: 356-363. [PubMed]

95. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, et al. (2013) Justin-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88: 754-757. [PubMed]

96. Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, et al. (2013) Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the preemptive use of plerixafor. Leuk Lymphoma 55: 331-336. [PubMed]

97. Yannaki E, Papayannopoulou T, Jonlin E, Zervou F, Karponi G, et al. (2012) Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 20: 230-238. [PubMed]

98. Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, et al. (2012) Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant 47: 18-23. [PubMed]

99. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, et al. (2009) A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 11: 992-1001. [PubMed]